5月14日 - ** 百健（BIIB.O）股价盘前上涨10%，至227.28美元
(link) ** 该公司表示，计划将其用于治疗阿尔茨海默病的实验性药物diranersen推进至后期开发阶段
** 称该疗法在中期试验中显著减少了与阿尔茨海默病相关的tau蛋白堆积，并显示出对患者认知功能的改善
** BIIB表示，在用于评估痴呆症严重程度的标准量表上，该疗法未能证明高剂量比低剂量更有效
** 同样在研有阿尔茨海默病疗法的Denali Therapeutics（DNLI.O）股价在盘前交易中上涨8.6%
** 截至上一交易日收盘，BIIB今年以来累计上涨16.2%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.